NEW YORK, Oct.16 (GenomeWeb News) - Human Genome Sciences has acquired from DiaDexus exclusive, worldwide rights to develop and commercialize diagnostic immunohistochemical tests based on the company's TRAIL Receptor-1 and TRAIL Receptor-2 proteins
DiaDexus retains exclusive commercial rights for diagnostics based on TRAIL-R1 and TRAIL-R2 in other formats, the firm said. Terms of the deal call for DiaDexus to receive an upfront payment, clinical and commercial milestone payments, and royalties.
Human Genome Sciences originally discovered the TRAIL Receptor-1 and TRAIL Receptor-2 proteins. DiaDexus acquired diagnostic rights to them through an agreement with GlaxoSmithKline.